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Abstract
Wnts comprise a family of 20 lipid-modified glycoproteins in mammals and play critical roles
during embryological development and organogenesis of several organ systems, including the
heart. They are required for mesoderm formation and have been implicated in promoting
cardiomyogenic differentiation of mammalian embryonic stem cells, but the underlying
mechanisms regulating Wnt signaling during cardiomyogenesis remain poorly understood. In this
report, we show that in a pluripotent mouse embryonal carcinoma stem cell line, SFRP2 inhibits
cardiomyogenic differentiation by regulating Wnt3a transcription. SFRP2 inhibited early stages of
cardiomyogenesis, preventing mesoderm specification and maintaining the cells in the
undifferentiated state. Using a gain- and loss-of-function approach, we demonstrate that although
addition of recombinant SFRP2 decreased Wnt3a transcription and cardiomyogenic
differentiation, silencing of Sfrp2 led to enhanced Wnt3a transcription, mesoderm formation, and
increased cardiomyogenesis. We show that the inhibitory effects of SFRP2 on Wnt transcription
are secondary to interruption of a positive feedback effect of Wnt3a on its own transcription.
Wnt3a increased its own transcription via the canonical pathway and TCF4 family of transcription
factors, and the inhibitory effects of SFRP2 on Wnt3a transcription were associated with
disruption of downstream canonical Wnt signaling. The inhibitory effects of Sfrp2 on Wnt3a
expression identify Sfrp2 as a “checkpoint gene,” which exerts its control on cardiomyogenesis
through regulation of Wnt3a transcription.
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The Wnt signaling system in mammals, comprising 20 lipid-modified glycoproteins, exerts
pleiotropic effects on a wide variety of cellular processes, including proliferation, apoptosis,
self-renewal, and differentiation [1,2]. These proteins play a crucial role during
embryological development [3] and organogenesis of several organ systems, including
cardiac morphogenesis [4]. In birds and amphibians, Wnts inhibit heart formation [5–7],
whereas canonical Wnt signaling is required for mesoderm specification [8,9] and promotes
cardiomyogenic differentiation of pluripotent mouse embryonic stem cells [10,11].
Classically, Wnts have been divided into two groups, canonical and noncanonical.
Canonical Wnt signaling pathways involve binding of Wnt to its Frizzled receptor in
association with LRP5/6, with subsequent translocation of Axin to the cell membrane and
inhibition of GSK3β. GSK3β, in the absence of Wnt ligand, phosphorylates β-catenin,
directing it for subsequent degradation via the ubiquitin proteasomal pathway. In the
presence of Wnt ligand, GSK3β is inhibited. This leads to accumulation of cytoplasmic β-
catenin, which subsequently translocates to the nucleus, binds to corepressors such as
Groucho, and initiates target gene transcription via the TCF/LEF family of transcription
factors. Wnt signaling is finely tuned through the presence of Wnt antagonists, which are
divided into two classes, the Dickkopf (Dkk) class and the SFRP class [12]. Whereas Dkk
specifically antagonizes the canonical pathway by interrupting the binding of Wnt/Fz to
LRP5/6 coreceptor, SFRPs bind to Wnts and potentially antagonize both the canonical and
the noncanonical pathways. In mammals, the SFRP class mainly comprises the family of
SFRP proteins, of which five have been identified so far. On the basis of sequence
homology, the family can be divided into two groups; SFRP1, SFRP2, and SFRP5 form one
group, whereas SFRP3 and SFRP4 form another [12]. SFRPs, in the N-terminal half of the
protein, possess a cysteine-rich region very similar to one present on the Frizzled receptor
and are thought to function as extracellular Wnt antagonists by binding Wnts [13].
Despite the existence of extracellular modulators of Wnt signaling, factors regulating Wnt
transcription and downstream signaling in mammalian cardiomyogenesis are largely
unknown. SFRPs are present in the heart-forming fields and adjoining regions in the
developing embryo [4]. For instance, SFRP2 is expressed in a broad ectodermal territory
overlapping with the heart-forming fields, whereas SFRP1 and SFRP3 are expressed in all
three germ layers [5,14,15]. Despite their presence in these regions, the interaction of SFRPs
with Wnts, the mechanisms of modulation of Wnt effect, and their role in regulating cardiac
morphogenesis in mammals are unclear.
In this study, we investigated transcriptional regulation and modulation of Wnt signaling
during cardiomyogenic differentiation. We show for the first time that SFRP2, although an
extracellular Wnt antagonist, inhibits Wnt3a transcription and regulates cardiomyogenic
differentiation. We studied this interaction in a pluripotent mouse embryonal carcinoma
stem cell line (P19CL6), which has served as a well-validated model for the dissection of
pathways determining cardiomyogenic differentiation [16]. We demonstrate that (a) Wnt3a
exerts positive feedback on its own transcription and (b) SFRP2, by interrupting this positive
feedback loop, inhibits Wnt3a transcription and regulates cardiomyogenic differentiation.
Cells treated with recombinant SFRP2 protein had dramatically decreased cardiomyogenic
differentiation and failed to express Wnt3a. Conversely, silencing of SFRP2 led to enhanced
Wnt3a transcription and cardiomyogenic differentiation. Although it belongs to the same
family as SFRP2, SFRP1 did not exert these inhibitory effects on differentiation. These data
describe a novel function of SFRP2 in regulating Wnt transcription during cardiomyocyte
specification and differentiation.
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P19CL6 and stable transfectant MLC2v-GFP P19CL6 cell lines were kindly provided by Dr.
Richard Kitsis (Albert Einstein College of Medicine, Bronx, NY) and Dr. Christine
Mummery (The Netherlands Institute of Developmental Biology, Utrecht, The Netherlands).
Recombinant WNT3A, recombinant SFRP1, SFRP2, and Dkk-1 were purchased from R&D
Systems Inc. (Minneapolis, http://www.rndsystems.com). Quantitative polymerase chain
reaction (PCR) primers for Wnt3a, Nanog, Sfrp2, GATA4, MHC, MLC2a, TBX5, and cardiac
actin were bought from Applied Bio-systems (Foster City, CA,
http://www.appliedbiosystems.com). TOP (a luciferase reporter plasmid driven by 4 ×
copies of TCF-binding sequence), FOP flash (the same vector containing mutated TCF4-
binding domain) vectors, Wnt3a cDNA in pUSE-amp, and dominant negative TCF4 plasmid
were purchased from Upstate Biotechnology (Billerica, MA, http://www.upstate.com). Short
interfering RNA (siRNA) oligonucleotides targeting Wnt3a and SFRP2 were bought from
Ambion (Foster City, CA, http://www.ambion.com). Vector backbone (pcDNA 6.2-GW/
EmGFP-micro-RNA [miR]) for micro-RNA expression for gene silencing was bought from
Invitrogen (Carlsbad, CA, http://www.invitrogen.com). β-Catenin antibody was purchased
from Cell Signaling Technology (Boston, http://www.cellsignal.com), and antibodies
against glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and TBP and cardiac
troponin T were bought from Abcam (Cambridge, MA, http://www.abcam.com). MF20
antibody was bought from Developmental Studies Hybridoma Bank (Iowa City, IA,
http://www.uiowa.edu/~dshbwww).
Cell Culture and Differentiation
P19CL6 cells were grown in 10-cm dishes in the presence of α Minimum Essential Medium
(Gibco, Grand Island, NY, http://www.invitrogen.com) supplemented with 10% fetal bovine
serum, penicillin, and streptomycin (growth medium). For induction of myogenic
differentiation, cells were initially seeded on 6-cm dishes (4 × 103–4 × 104 cells per dish)
and grown in the presence of growth medium and 1% dimethyl sulfoxide (DMSO) for 14
days (differentiation medium). Stably transfected P19CL6 cells expressing MLC-2v-GFP
were grown in the presence of Dulbecco's modified Eagle's medium:Ham's F-12 medium
(Invitrogen) supplemented with 7.5% fetal calf serum, essential amino acids, and 600 μg/ml
G418.
Conventional and Quantitative Reverse Transcription-PCR
RNA extraction was performed with the help of the RNeasy Plus kit (Qiagen, Hilden,
Germany, http://www1.qiagen.com), and cDNA synthesis was carried out with Superscript
III (Invitrogen) according to the manufacturer's instructions. Conventional PCR was
performed with 100 ng of cDNA, each reaction being run for 30 cycles. GAPDH was run for
20 cycles. For real-time PCR, 100 ng of cDNA was used as a template, and gene expression
was analyzed using the ΔCT method with light cycler (ABI Prism 7700; Applied
Biosystems). GAPDH was used for internal control to normalize for equal RNA loading.
Controls without reverse transcription (RT) (cDNA synthesis without adding reverse
transcriptase) were used for each gene analyzed to exclude genomic DNA contamination.
Conventional PCR primer sequences are available upon request.
Western Blotting and Immunofluorescent Staining
Western blotting and immunofluorescent staining was performed using standard protocols as
previously described [10]. For detection of nuclear and cytoplasmic β-catenin, the nuclear
and cytoplasmic fractions were separated using the Fraction Prep cell fractionation kit
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(Biovision Inc., Mountain View, CA, http://www.biovision.com). In each case, signal was
detected using a chemiluminescent detection system (ECL; Amersham Biosciences,
Piscataway, NJ, http://www.amersham.com). Area densitometry analysis was performed
using Fluostar software (UVP Bioimaging Systems, Upland, CA, USA). For
immunofluorescent staining, cells following a 14-day treatment in differentiation medium
(DM) with or without SFRP2 were trypsinized, reseeded onto two-well chamber slides (Lab-
Tek II; Nalge Nunc International, Rochester, NY, http://www.nalgenunc.com), fixed with
4% paraformaldehyde, stained with the primary and secondary antibodies for 1 hour each,
and visualized using a Zeiss Axiovert 200 microscope (Carl Zeiss, Jena, Germany,
http://www.zeiss.com). For MF20 staining, cells were fixed with methanol (precooled at –
20°C) for 15 minutes.
Luciferase Assay
Cells were seeded onto six-well plates overnight at a seeding density of 1 × 105 cells per
well and were transfected the next day using Lipofectamine 2000 (Invitrogen) in low-serum
Opti-MEM medium (Gibco) for 6 hours. Each well contained 4 μg of TOP or FOP Flash
vector and 100 ng of pRL-CMV as the cotransfected control. Medium containing Wnt,
lithium, or differentiating medium was added to the wells 6 hours after transfection. Cells
were harvested and lysed after overnight treatment with Wnt/lithium and after a 48-hour
treatment with differentiating medium. Firefly luciferase activity (TOP and FOP) was
measured and normalized to Renilla luciferase activity for each sample using the Dual
luciferase system (Promega, Madison, WI, http://www.promega.com).
Vector-Based Micro-RNA Production, siRNA, and Dominant Negative TCF4 Transfection
Protocols
For creating a stably transfected P19CL6 cell line expressing a vector encoding a micro-
RNA against SFRP2, we used the pcDNA 6.2-GW/EmGFP-miR vector backbone
(Invitrogen) that contains enhanced green fluorescent protein (EGFP) and a blasticidin
resistance cassette. Micro-RNA sequences targeting SFRP2 were generated using computer-
based algorithms (Invitrogen) and cloned into the vector backbone. Cells were transiently
transfected with several constructs and were screened by RT-PCR to identify one with the
highest efficiency in silencing SFRP2. Owing to cocistronic expression of EGFP, cells
transiently transfected with the chosen SFRP2 micro-RNA construct were sorted by flow
cytometry with green fluorescent protein (GFP) expression and subsequently used for
differentiation experiments. As the vector backbone contains a blasticidin resistance
cassette, the cells were grown in differentiation medium or growth medium containing
blasticidin for maintenance of selected cells. As a control, cells transfected with the same
vector encoding a micro-RNA targeting the β-galactosidase gene were used and grown in
medium containing blasticidin. For transient knockdown of SFRP2 expression, we also used
siRNA oligos. Cells were seeded onto six-well plates at a density of 1 × 105 cells per well
and transfected using Lipofectamine 2000 and 50 nM siRNA. A scrambled siRNA was used
in each case at the same concentration. Cells were incubated overnight with the transfection
mixture followed by addition of fresh medium the next day. Cells were transfected with
dominant negative TCF4 or empty vector using a similar protocol and were used for
differentiation experiments 48 hours following transfection.
Results
SFRP2 Inhibits Myogenic Differentiation of P19CL6 Mouse Embryonic Stem Cells
We first determined the effects of SFRP1 and SFRP2 on myogenic differentiation. We
treated P19CL6 cells with cardiomyogenic differentiation medium containing 1% DMSO
for 14 days in the absence or presence of SFRP2 (3 nM) (with cells being replenished with
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fresh medium every other day). Previous studies have demonstrated that these cells at
baseline do not express myocyte-specific transcription factors or structural proteins but can
be induced to differentiate into cardiomyocytes when treated with medium containing
DMSO [10,11]. Consistent with these reports, using RT-PCR we observed induction of
expression of cardiomyocyte-specific transcription factors, such as GATA4 and TBX5, and
structural proteins, such as myosin heavy chain (MHC)α and myosin light chain (MLC)2a,
following 8 days of treatment with differentiation medium (Fig. 1A). In the presence of
differentiation medium, GATA4, TBX5, MHC, and MLC2a mRNA expression increased
over the course of 14 days, consistent with cardiomyogenic differentiation (Fig. 1A).
However, concomitant treatment with recombinant SFRP2 protein dramatically inhibited the
expression of these transcription factors and structural proteins (Fig. 1A). The expression of
MLC2a following treatment with differentiation medium for 14 days was inhibited by
SFRP2 in a concentration-dependent fashion (Fig. 1B). Moreover, when we treated cells
with SFRP1, a closely related family member, no significant inhibitory effects on
myogenesis were observed, suggesting that the effects are specific to SFRP2 rather than a
property exhibited by this family of molecules. SFRP1, in contrast to SFRP2, did not
decrease the expression of transcription factors and structural proteins characteristic of
myogenic differentiation (Fig. 1C). To further quantitate the degree of inhibition exerted by
SFRP2, we treated P19CL6 cells expressing GFP driven by a MLC2v promoter (a kind gift
from Dr. Mummery, Utrecht, The Netherlands) with differentiation medium. Following
treatment with DM for 14 days, approximately 20% of the cells expressed GFP, whereas a
dramatic reduction in GFP expression was observed in cells treated concomitantly with
SFRP2 (Fig. 1G–1I, 1K). Using Western blotting and immunofluorescent staining
techniques, we also observed dramatic reduction in expression of cardiac-specific structural
proteins. Cells treated with DM for 14 days expressed cardiac troponin T protein, but
troponin T expression was dramatically inhibited with concomitant treatment with SFRP2 (3
nM) (Fig. 1J). Similarly, differentiated P19Cl6 cells stained for cardiac troponin (Fig. 1N)
with characteristic striations (Fig. 1N, inset) and MF20 (sarcomeric myosin) (Fig. 1P)
compared with minimal differentiation observed when cells were grown in the absence of
DM (Fig. 1M). Concomitant treatment with SFRP2 resulted in a dramatic reduction in
expression of these proteins (Fig. 1O, 1Q). Finally, we did not observe any beating
cardiomyocytes following treatment with DM and SFRP2, but typical beating clusters
(supplemental online Fig. 1A, 1B) were seen 14 days following treatment with DM alone.
SFRP2 Prevents Mesodermal Commitment and Aggregate Formation of P19CL6 Cells
Treated with Cardiomyogenic Differentiation Medium
We next investigated the stage at which SFRP2 inhibits cardiomyogenic commitment and
differentiation. One of the early events that take place during cardiomyogenic differentiation
of P19 embryonic stem cells is aggregate formation and differentiation into mesodermal
lineage [17]. No distinct embryoid body-like structures were observed in P19CL6 cells in
the absence of differentiating medium (Fig. 2A); however, when these cells were treated
with differentiating medium, cellular aggregates resembling embryoid body-like structures
formed by 4 – 6 days of treatment (Fig. 2B). However, concomitant treatment of cells with
differentiation medium and SFRP2 significantly decreased embryoid body formation (p < .
05), and the cells were morphologically indistinguishable from those grown in the absence
of differentiating medium (Fig. 2C, 2D). In fact, SFRP2 decreased the number of cellular
aggregates in cells treated with differentiation medium to that seen in control cells (Fig. 2D).
As the appearance of embryoid bodies has been suggested to be associated with mesodermal
commitment, we determined the expression of various mesodermal markers by RT-PCR.
Following 6 days of treatment with differentiation medium, we observed dramatic
upregulation of the mesodermal marker gene Brachyury. Expression of mesp1, a marker of
cardiac-specific mesoderm, as well as expression of Wnt8a, also significantly increased. We
Deb et al. Page 5













also noted induction of carbonic anhydrase III expression, an early marker of mesoderm
specification and one expressed in developing mouse embryonic muscle [18]. However,
addition of recombinant SFRP2 (3 nM) to cells treated with differentiation medium
completely abolished upregulation of genes associated with mesodermal or myogenic
specification, such as brachyury, mesp1, carbonic anhydrase III, and Wnt8a (Fig. 2E). These
data suggest that SFRP2 inhibits myogenic commitment of P19CL6 cells very early during
the process of differentiation by preventing aggregation and mesodermal commitment of
these cells. Differentiation of these cells into other related myogenic lineages, such as
skeletal muscle, in the presence of SFRP2 was also excluded by measuring expression of
key skeletal muscle regulatory genes, such as myogenin, MRF4, and MYF5 (data not
shown). We next investigated whether SFRP2, by inhibiting cardiomyogenic differentiation,
maintains the cells in the undifferentiated state. We determined Nanog expression in cells
treated with differentiation medium for 6 days. Nanog is a transcription factor that is
associated with the pluripotent state in embryonic stem cells and is downregulated with the
onset of differentiation [19]. Using quantitative PCR, we showed that treatment with
differentiating medium led to near complete disappearance of Nanog expression in P19CL6
cells, whereas cells concomitantly treated with SFRP2 exhibited fivefold higher Nanog
expression compared with cells treated with differentiation medium alone (Fig. 2F) (p < .
05).
Silencing of SFRP2 in P19CL6 Cells Enhances Cardiomyogenesis
As P19CL6 cells express SFRP2, we next investigated whether silencing of SFRP2
expression leads to enhanced cardiomyogenic differentiation. For silencing of Sfrp2
expression, we transfected cells with a plasmid vector encoding a micro-RNA targeting
Sfrp2. We obtained transfection efficiencies of 60%–70%, and cells expressing the micro-
RNA targeting Sfrp2 also possessed cocistronic expression of EmGFP (Fig. 3Ai–3Aiv).
Cells transfected with a vector construct encoding a micro-RNA directed against the β-
galactosidase gene served as controls. We obtained nearly 90% knockdown of Sfrp2 gene
expression with this technique (Fig. 3B). As the vector backbone also contained a blasticidin
resistance cassette, transfected cells (expressing lacZ miR or SFRP2 miR) following
transient transfection were selected on the basis of GFP expression by flow cytometry and
treated with differentiation medium containing blasticidin (200 μg/ml) for a period of 14
days. Cells were harvested at the end of 14 days and analyzed by quantitative PCR for the
expression of transcription factors and structural proteins characteristic of myogenic
differentiation. We also confirmed, by RT-PCR, persistent knockdown of SFRP2 expression
at the end of 14 days (data not shown). As shown in Figure 3C–3G, differentiation medium
in control cells (lacZ micro-RNA-transfected) induced an increase of nearly 100-fold in
expression of transcription factors such as GATA4 and TBX5 compared with
undifferentiated cells. However, cells harboring a knockdown of SFRP2 expression
exhibited a further significant increase of 2–2.5-fold (p < .05) in gene expression of
transcription factors such as GATA4 and TBX5, as well as structural proteins such as MHC
and MLC2a. These results, taken together with our gain-of-function experiments, suggest
that SFRP2 regulates cardiomyogenesis by exerting an inhibitory effect.
SFRP2 Inhibits Canonical Wnt Signaling During Cardiomyogenic Differentiation
Canonical Wnt signaling has been demonstrated to be necessary for primitive streak
formation in vivo and embryonic stem cell-derived mesoderm formation in vitro [8].
Moreover, cardiomyogenic differentiation of P19CL6 cells is associated with activation of
canonical Wnt signaling. As SFRP2 is a known extracellular Wnt antagonist [12], we
hypothesized that it could be exerting inhibitory effects on cardiomyogenic differentiation
by disruption of downstream canonical Wnt signaling. We initially determined cytoplasmic
and nuclear β-catenin levels by Western blotting in P19CL6 cells that had been treated with
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differentiation medium for 4 days in the absence or presence of SFRP2. As previously
reported [10], we noted increased β-catenin in the cytoplasmic fraction of the lysate of cells
treated with differentiation medium. Western blotting also demonstrated increased
accumulation of nuclear β-catenin, consistent with translocation of cytoplasmic β-catenin to
the nucleus. In contrast, SFRP2 significantly decreased the accumulation of both nuclear and
cytoplasmic β-catenin (Fig. 4A, 4B; p < .05).
To further confirm the inhibitory effects of SFRP2 on canonical Wnt signaling in
differentiating P19CL6 cells, we used a reporter assay measuring canonical Wnt-dependent
transcriptional activity. P19CL6 cells were transfected with the TOP and FOP Flash vectors
and then treated with differentiation medium for 48 hours. The TOPFlash vector has
luciferase expression driven by 4 × TCF4 DNA-binding sequence. Cells transfected with the
FOPFlash vector containing mutated TCF4-binding sequences served as negative control to
demonstrate specificity of the reporter assay. We observed a fivefold increase in lucif-erase
activity in P19CL6 cells treated with cardiomyogenic differentiating medium, whereas
addition of recombinant SFRP2 protein significantly attenuated the increase in luciferase
activity by almost 50% (p < .05) (Fig. 4C). Canonical Wnt signaling results in inhibition of
GSK3β with subsequent inhibition of ubiquitin-mediated proteolytic degradation of
cytoplasmic β-catenin. To demonstrate that SFRP2 did not exert any inhibitory effects
downstream of GSK3β, we also treated cells with lithium chloride (20 mM). Lithium
chloride has been shown to inhibit GSK3β and to simulate canonical Wnt signaling. As
shown in Figure 4C, lithium chloride-treated cells exhibited an increase of nearly fivefold in
reporter activity, similar to cells treated with differentiation medium. Interestingly, cells
treated with SFRP2 alone in the absence of lithium chloride had a 18% decrease in reporter
activity, suggesting the possible presence of autocrine canonical Wnt signaling. However, in
contrast to its effects on reporter activity in cells treated with differentiation medium, SFRP2
did not significantly decrease the lithium chloride-induced increase in reporter activity (Fig.
4C). The 15% attenuation of LiCl-induced reporter activity was similar to the decrease in
reporter activity seen in cells treated with SFRP2 alone (p > .05). Taken together, these
observations suggest that SFRP2 inhibits canonical Wnt signaling in differentiating P19CL6
cells upstream of GSK3β.
SFRP2 Regulates Wnt3a Transcription by Inhibiting Wnt3a Autopositive Feedback
We next focused on the interaction of SFRP2 with Wnts that are potentially critical for
successful cardiomyogenic differentiation. Canonical Wnts such as Wnt3a are expressed in
the first few days following treatment with differentiation medium. Naito et al. have
previously demonstrated that Wnt3a is sufficient to induce myogenesis in P19CL6 cells even
in the absence of differentiation medium [11]. Moreover, mice lacking Wnt3 fail to develop
primitive streak and mesoderm. We thus explored the interaction of Wnt3a and SFRP2 and
unexpectedly observed that SFRP2 inhibited transcription of Wnt3a mRNA within 2 days of
treatment with differentiation medium. P19CL6 cells were treated with differentiation
medium for 4 days in either the presence or the absence of SFRP2. Cells were harvested at
2, 3, and 4 days and analyzed for expression of Wnt3a mRNA by RT-PCR. In contrast to
untreated control cells, cells treated with SFRP2 (3 nM) failed to exhibit any expression of
Wnt3a mRNA (Fig. 5A). It is interesting to note that even though SFRP2 completely
suppressed DM-induced Wnt3a expression between day (D)2 and D4 following induction of
differentiation, maximal suppression of expression of mesodermal marker genes, such as
Brachyury and Mesp1, occurred at a slightly later time point (D6). The expression of
mesodermal genes at D2–D4 in the absence of Wnt3a expression suggests that SFRP2's
inhibition of Wnt3a expression is independent of its effects on mesoderm formation
(supplemental online Fig. 5).
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As SFRP2 is considered to be an extracellular Wnt antagonist and possesses strong binding
affinity for Wnt3a [20], we hypothesized that its inhibitory effects on Wnt3a transcription
are potentially secondary to interruption of a positive feedback effect of Wnt3a on its own
transcription. To demonstrate that Wnt3a increases its own mRNA, we treated P19CL6 cells
with different concentrations of recombinant Wnt3a protein for 48 hours. Cells were
subsequently harvested and examined for Wnt3a mRNA expression. As shown in Figure 5B,
P19CL6 cells do not express Wnt3a mRNA at baseline. However, treatment with 10 nM
Wnt3a protein dramatically increased Wnt3a mRNA. Using semiquantitative analysis, we
showed that the increase in Wnt3a mRNA following treatment with 10 nM Wnt3a protein
was significantly higher than the induction of Wnt3a mRNA following treatment with
differentiation medium for the same duration of time (Fig. 5C). As a positive control, we
also noted an increase of vascular endothelial growth factor (VEGF) mRNA following
treatment with Wnt3a protein, VEGF being a known downstream target of Wnt3a.
To further demonstrate that SFRP2 not only inhibits but regulates Wnt3a transcription, we
used a loss-of-function approach to determine the effects of silencing SFRP2 expression on
Wnt3a expression. P19CL6 cells in the undifferentiated state do not express Wnt3a, but
induction of Wnt3a expression occurs early on during cardiomyogenic differentiation. As
illustrated in Figure 5D, Wnt3a expression peaks by 3 days and disappears by 10 days.
Again, P19CL6 cells harboring knockdown of Sfrp2 were subsequently treated with
differentiation medium for 2 days, at which time the cells were harvested and analyzed for
Wnt3a expression by quantitative PCR. We chose this time point to be on the ascending
limb of the curve for Wnt3a transcription (Fig. 5D). Untransfected controls, as well as cells
transfected with scrambled RNA, exhibited a 200-fold increase in Wnt3a expression. SFRP2
siRNA-transfected cells had a further fivefold significant (p < .05) increase in Wnt3a mRNA
expression compared with untransfected or scrambled RNA-transfected controls (Fig. 5E).
Taken together, these data strongly support the notion that Wnt3a exerts a positive feedback
effect on its own transcription that is regulated by SFRP2. As SFRP2 silencing leads to
increased DM-induced Wnt3a expression, we next investigated whether SFRP2 silencing
leads to increased expression of mesodermal marker Brachyury, a known Wnt3a target gene
[21]. Indeed, we did observe dramatic upregulation of Brachyury expression in cells
harboring SFRP2 knockdown just 2 days following treatment with DM (Fig. 5F). This
observation is consistent with our earlier finding of increased cardiomyogenesis in cells
harboring SFRP2 knockdown; enhanced cardiomyogenesis may be mediated by increased
Brachyury expression and mesoderm formation.
Wnt3a Activates Canonical Signaling to Exert a Positive Feedback on Its Own
Transcription
Having demonstrated that Wnt3a increases its own transcription in a positive feedback
effect, we next investigated the mechanism of Wnt3a-induced increase in Wnt3a mRNA
expression. We hypothesized that Wnt3a activates the canonical signaling pathway to
increase its own transcription. We treated P19CL6 cells with Wnt3a (10 nM) in the presence
or absence of Dkk1 (500 ng/ml) for 48 hours. Dkk1 binds to LRP5/6 and is thought to be a
specific inhibitor of canonical Wnt signaling, leaving noncanonical Wnt signaling intact.
Cells were subsequently harvested and examined for Wnt3a mRNA expression by
quantitative PCR. As shown in Figure 6A, recombinant WNT3A protein increased Wnt3a
mRNA in P19CL6 cells by almost 20-fold after 48 hours (p < .05). However, concomitant
treatment with Dkk-1 completely abolished the increase in Wnt3a mRNA (p < .05).
Activation of canonical Wnt signaling results in translocation of β-catenin to the nucleus,
where it initiates target gene transcription, mediated by the TCF/LEF group of transcription
factors. We next determined whether transcription of Wnt3a is mediated by the TCF group
of transcription factors. In particular, previous reports have demonstrated the importance of
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TCF4 in β-catenin signaling. We therefore transfected cells with a dominant negative form
of TCF4 and treated them with differentiating medium for 48 hours. Cells transfected with
the empty vector served as control. As shown in Figure 6B, differentiating medium induced
a dramatic upregulation of Wnt3a in cells transfected with empty vector. However, cells
transfected with the dominant negative form of TCF4 experienced a 90% reduction of
Wnt3a mRNA expression (p < .05), demonstrating the critical importance of the canonical
system and TCF family of transcription factors in exerting this feedback.
Discussion
In this study, we report a novel form of interaction between Wnts and the Sfrp family of
Wnt signaling modulators. We demonstrate that SFRP2 inhibits Wnt3a transcription by
interrupting a positive feedback effect of Wnt3a on its own transcription. Wnt3a-induced
positive feedback is intriguing, as Wnt3a is not known to be its own target gene. Using gain-
and loss-of-function approaches, we show that SFRP2, by regulating this positive feedback,
modulates cardiomyogenic differentiation. Teleologically, a positive feedback effect of
Wnt3a on its own transcription is advantageous, as it provides the cells with a mechanism to
rapidly amplify critical differentiation signals. During the preparation of this article, Ueno et
al. reported Wnt3a-induced transcriptional inhibition of Wnt1 and Wnt3a in differentiating
embryoid bodies of mouse embryonic stem cells [22]. Although our results are apparently
discrepant with the conclusions drawn by Ueno et al. [22] in regard to Wnt3a-induced
transcriptional feedback, on closer inspection, the existence of temporally separated, both
early positive and late negative feedback loops, appears to be a strong possibility.
Unchecked Wnt signaling during later stages of myogenesis inhibits myogenesis and directs
differentiation along a hematopoietic lineage [17,22]. Thus, an early positive and late
negative regulation of Wnt3a transcription would be optimal for cardiomyocyte
specification and differentiation. In our study, silencing Sfrp2 expression in P19Cl6 cells
alone did not induce Wnt3a transcription but required concomitant treatment with DMSO.
Moreover, Wnt3a expression, although significantly higher in cells lacking SFRP2, was not
sustained and followed a temporal profile similar to that of control cells, suggesting the
presence of other regulatory molecules. Nevertheless, the transient but significant increase in
Wnt3a transcription was sufficient to enhance cardiomyogenic differentiation.
Although our study suggests the role of SFRP2 as a cardiomyogenic “checkpoint” molecule
regulating cell differentiation via modulation of key Wnt feedback loops, it raises other
questions. What are the factors that determine whether Wnts exert negative or positive
feedback on a cell? What are the other checkpoints for control of a Wnt-positive feedback
within the cell? Differences in the ability of Wnts to mount positive feedback loops and of
SFRPs to control such transcriptional networks might explain divergent or opposing effects
of Wnts in development and disease. For instance, a recently published report demonstrates
much higher binding affinity of Wnt3a for SFRP2 than SFRP1 [20]; this might explain the
differences between SFRP1 and SFRP2 with regard to inhibition of cardiomyogenesis and
Wnt3a transcription as observed in our study. The opposite roles of Wnt in heart formation
in mammalian systems and chick/Xenopus have been attributed to species differences and
biphasic effects of Wnt signaling [17]. Our data suggest that transcriptional regulation of
Wnts by Wnt modulators is another novel area of Wnt/Wnt antagonist interaction that
should be considered to explain such differences. In this regard, we have recently described
an antiapoptotic effect of SFRP2 on cardiomyocytes [23]. The contrasting effects of SFRP2
on cardiomyogenesis and cell survival may be related to its antagonistic effects on
expression of different Wnts.
It is also tempting to speculate whether transcriptional regulation of Wnts by SFRPs, as
noted in this study, is important in regulation of differentiation in other cell systems or in
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aberrant cell growth and dedifferentiation seen in tumors. SFRPs are considered to have
tumor-suppressive properties, and epigenetic silencing of Sfrps including Sfrp2 has been
observed in colorectal and esophageal carcinomas [24]. It is thought that Sfrp silencing leads
to constitutively active autocrine Wnt signaling, a phenomenon shown to exist in human
cancer cells [25] and thought to have a causal relation with development of cancer. Our
study raises the questions of whether Sfrps mediate tumor-suppressive properties by
potentially regulating Wnt transcription and whether silencing of Sfrps leads to enhanced
Wnt transcription and a cycle of positive feedback signaling. Clearly, future studies need to
address the role of regulators of Wnt transcription in development and diseased states.
Conclusion
In summary, our study provides evidence for the existence of Wnt3a-positive feedback
signaling in cardiomyogenic differentiation of murine P19 embryonal carcinoma stem cells
and shows a novel form of transcriptional cross-talk between SFRP2 and WNT3A. With
recent observations that Wnts regulate stem cell renewal [26], identification of Wnt
feedback loops, their principal molecular regulators and downstream effects, may be key to
understanding mechanisms determining cell choices of self-renewal versus differentiation.
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SFRP2 inhibits myogenic differentiation of P19Cl6 cells. Representative reverse
transcription-polymerase chain reaction (n = 3) demonstrating (A): expression of myogenic
transcription factors and structural proteins in P19Cl6 cells treated with differentiation
medium (DM) in the absence or presence of SFRP2 (3 nM), (B): expression of MLC2a in
P19Cl6 cells treated with DM for 14 days in the absence or presence of increasing
concentrations of SFRP2, and (C) expression of myocyte-specific structural proteins and
transcription factors in P19Cl6 cells treated with DM for 14 days in the presence of SFRP1
(3 nM) or SFRP2 (3 nM). (D–I): Phase-contrast views (×100) and green fluorescent protein
(GFP) expression in MLC2v-GFP P19Cl6 cells at (D, G) baseline; (E, H) treated with DM;
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(F, I) DM and SFRP2 (3 nM) for 14 days (n = 3). (J): Western blotting for cardiac Troponin
T expression in P19Cl6 cells treated with DM ± SFRP2; CTRL represents untreated cells.
(K): High-power view (×200) of (H) inset showing GFP-positive MLV 2v cells. (L–Q):
Immunofluorescent staining for Troponin T (red) and MF20 (green) in P19Cl6 cells treated
with DM for 14 days. (L): Cells stained without adding primary antibody. Cardiac Troponin
T staining of cells: (M): grown in growth medium without induction of differentiation, (N):
treated with DM (N inset) zoomed image of Troponin T-positive cardiomyocyte, (O) treated
with DM + SFRP2 (3 nM). MF20 staining of cells; (P) treated with DM; (Q) treated with
DM + SFRP2 (3 nM). (Nuclei are stained with DAPI for L–Q; total magnification of ×400
for fluorescent images). Abbreviations: Ab, antibody; CTRL, control (untreated cells); DM,
differentiation medium; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; MHCα,
myosin heavy chain; MLC2a, myosin light chain; Trop T, troponin T.
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SFRP2 inhibits aggregate formation and mesodermal specification in P19Cl6 cells treated
with DM for 6 days (n = 6). (A–C): Bright-field images (×200) showing morphology of
P19Cl6 cells grown as a monolayer at baseline (A), following treatment with DM (B), or
following treatment with DM and SFRP2 (3 nM) (C). (D): Number of aggregates per high
power field in P19Cl6 cells following treatment with DM in the presence or absence of
SFRP2. (*, p < .01 between DM-treated and DM + Sfrp2-treated groups.) (E): Reverse
transcription-polymerase chain reaction (PCR) demonstrating expression of genes associated
with mesodermal specification in P19Cl6 cells treated with DM for 6 days in the absence or
presence of SFRP2 (3 nM). (F): Nanog expression by quantitative PCR in P19Cl6 cells
treated with DM for 6 days with or without SFRP2 (3 nM) (*, p < .05; n = 3; bars represent
SD). Abbreviations: CTRL, control; DM, differentiation medium; GAPDH,
glyceraldehyde-3-phosphate dehydrogenase.
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Knockdown of SFRP2 enhances myogenic differentiation of P19Cl6 cells. (A): P19Cl6 cells
transfected with a plasmid vector possessing cocistronic expression of GFP and micro-RNA
targeting SFRP2 showing phase-contrast (Ai), Hoechst-stained nuclei (Aii), GFP (Aiii), and
merged figure (Aiv). (B): Quantitative polymerase chain reaction (QPCR) demonstrating
knockdown of SFRP2 gene expression in P19Cl6 cells following transfection with vector
encoding SFRP2 micro-RNA or lacZ (control) micro-RNA (n = 3; *, p < .05). (C–G):
QPCR demonstrating gene expression of cardiomyogenic transcription factors and structural
proteins in P19Cl6 cells treated with differentiation medium for 14 days, following
knockdown of either SFRP2 or LacZ expression using vector-based micro-RNA (n = 3; *, p
< .05 for all groups; bars represent SD). Abbreviations: MHC, myosin heavy chain; MLC,
myosin light chain.
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SFRP2 interrupts canonical Wnt signaling in P19Cl6 cells treated with DM. (A):
Representative Western blotting (n = 3) for β-catenin in nuclear and cytoplasmic fractions of
cell lysates following treatment with DM for 48 hours in the absence or presence of SFRP2
(3 nM). GAPDH and Tata-binding proteins served as loading CTRLs. (B): Densitometry
analysis of Western blots in (A) (*, p < .05 for DM + SFRP2 groups compared with groups
treated with DM alone in both nuclear and cytoplasmic fractions; bars represent SE). (C):
Luciferase activity (fold change compared with untreated CTRLs) in P19Cl6 cells treated
with DM or LiCl (20 mM) for 48 hours in the absence or presence of SFRP2 (3 nM) (n = 6;
each experiment performed in triplicate; *, p < .05). FOP activity (red) served as negative
CTRL. Abbreviations: CTRL, control; DM, differentiation medium; gapdh,
glyceraldehyde-3-phosphate dehydrogenase; ns, not significant.
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SFRP2 regulates Wnt3a transcription. (A): Representative reverse transcription-polymerase
chain reaction (RT-PCR) (n = 3) for Wnt3a in P19Cl6 cells treated with DM in the absence
or presence of SFRP2 (3 nM) for 2, 3, and 4 D. (B): Representative RT-PCR (n = 3) for
Wnt3a in P19Cl6 cells treated with DM or recombinant WNT3A protein in increasing
concentrations. VEGF expression serves as a positive CTRL. GAPDH expression
demonstrates equal loading. (C): Semiquantitative analysis of Wnt3a mRNA expression in
cells treated with DM or increasing concentrations of Wnt3a, as seen in (B). Untreated cells
served as CTRLs. (D): Temporal profile of Wnt3a expression by quantitative polymerase
chain reaction (QPCR) in P19Cl6 cells treated with DM compared with untreated CTRLs (n
= 3; each experiment performed in triplicate). (E): QPCR demonstrating Wnt3a expression
in P19Cl6 cells following transient transfection with SFRP2 siRNA or sc siRNA (cells
treated with DM for 48 hours) (n = 3; *, p < .05 between Sfrp2 siRNA-treated and sc
siRNA-treated groups; bars represent SD). (F): Representative RT-PCR (n = 3) for
Brachyury expression in cells treated with SFRP2 siRNA compared with cells treated with
sc siRNA, 48 hours following addition of DM. CTRL cells were not treated with DM.
Abbreviations: CTRL, control; D, day; DM, differentiation medium; GAPDH,
glyceraldehyde-3-phosphate dehydrogenase; sc, scrambled; siR, short interfering RNA;
siRNA, short interfering RNA; VEGF, vascular endothelial growth factor.
Deb et al. Page 17














WNT3A induces Wnt3a mRNA expression via the canonical pathway. (A): Quantitative
polymerase chain reaction (QPCR) for Wnt3a in P19Cl6 cells treated with Wnt3a (10 nM)
for 48 hours in either the absence or presence of DKK-1 (cells were preincubated with
Dkk-1 for 1 hour before adding Wnt3a)(n = 3; each experiment in triplicate; *, p < .05
compared with CTRL cells; $, p < .05 compared with Wnt3a-treated group; bars represent
SD). (B): QPCR for Wnt3a expression in differentiation medium-treated P19Cl6 cells
transfected with either empty vector or Dom Neg TCF4 (n = 3; each experiment in triplicate;
*, p < .05). Abbreviations: CTRL, control; Dkk, Dickkopf; Dom Neg, dominant negative.
Deb et al. Page 18
Stem Cells. Author manuscript; available in PMC 2011 February 28.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
